Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma
This trial is active, not recruiting.
|Sponsor||State University of New York - Downstate Medical Center|
|Start date||June 1996|
|End date||October 2007|
|Trial size||20 participants|
|Trial identifier||NCT00456677, Heikki31|
Trial of effects of minocycline as "add-on" therapy to adults with asthma with a history of requiring at least one episode of oral steroid therapy to control the disease.
|Endpoint classification||safety/efficacy study|
|Intervention model||crossover assignment|
Decrease in oral steroid therapy requirements.
improvement in symptoms scores
improvement in spirometric outcomes
improvement in morning and evening peak flow
decrease in rescue inhaler usage
Male or female participants from 18 years up to 75 years old.
Inclusion Criteria: - Adult asthmatics - History of or current use of oral steroids to control symptoms Exclusion Criteria: - Pregnant women
|Official title||Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma|
|Principal investigator||Rauno Joks, MD|
|Description||This is a double-blind, placebo-controlled crossover study of adult asthmatics given minocycline 150 mg po BID or placebo as add-on therapy for eight weeks each. Each eight week arm is separated by a four week wash-out. Spirometry is performed at the baseline and end of each arm. Daily symptoms scores, peak flow rates, and oral steroid requirements are recorded. A standardized asthma quality of life symptoms assessment is made every four weeks (AQLQ, Juniper).|
Call for more information